EyePoint (EYPT) Cash & Current Investments (2010 - 2026)
EyePoint (EYPT) posted Cash & Current Investments of $222.5 million for Q1 2026, down 27.29% sequentially from $306.1 million in Q4 2025, and down 30.06% YoY from $318.2 million in Q1 2025.
Analysis
EyePoint (EYPT) Cash & Current Investments (2010 - 2026) Analysis & Trends
EyePoint has reported Cash & Current Investments for 17 years, with the latest figure at $222.5 million in Q1 2026.
- Quarterly Cash & Current Investments fell 30.06% year-over-year to $222.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222.5 million (down 30.06% YoY) and the FY2025 annual result came in at $306.1 million, down 17.48% from the prior year.
- Cash & Current Investments declined to $222.5 million in Q1 2026 per EYPT's latest filing, from $306.1 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $370.9 million in Q4 2024 and troughed at $122.5 million in Q1 2023.
- A 5-year average of $229.8 million and a median of $222.5 million in 2026 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments tumbled 35.81% in 2023, then jumped 144.44% in 2024.
- Over 5 years, Cash & Current Investments stood at $144.6 million in 2022, then surged by 129.0% to $331.0 million in 2023, then advanced by 12.04% to $370.9 million in 2024, then fell by 17.48% to $306.1 million in 2025, then slipped by 27.29% to $222.5 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $222.5 million, $306.1 million, and $204.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 180.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 180.47 Mn |
| Mar 31, 2026 | 222.55 Mn |
| Dec 31, 2025 | 306.09 Mn |
| Sep 30, 2025 | 204.02 Mn |
| Jun 30, 2025 | 255.73 Mn |
| Mar 31, 2025 | 318.19 Mn |
| Dec 31, 2024 | 370.91 Mn |
| Sep 30, 2024 | 253.79 Mn |
| Jun 30, 2024 | 280.25 Mn |
| Mar 31, 2024 | 299.35 Mn |
| Dec 31, 2023 | 331.05 Mn |
| Sep 30, 2023 | 136.04 Mn |
| Jun 30, 2023 | 142.54 Mn |
| Mar 31, 2023 | 122.48 Mn |
| Dec 31, 2022 | 144.56 Mn |
| Sep 30, 2022 | 157.26 Mn |
| Jun 30, 2022 | 171.17 Mn |
| Mar 31, 2022 | 190.78 Mn |
| Dec 31, 2021 | 211.59 Mn |
| Sep 30, 2021 | 119.71 Mn |